VBVivaan Bhatt

Vivaan Bhatt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Vivaan Bhatt has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Multi-Model Comparison of Deep and Classical Architectures for ECG Diagnostic Superclass Classification on PTB-XL

    by Vivaan Bhatt, Jordan B. Strom, Francisco Lopez-Jimenez, Demilade Adedinsewo, Venkatesh L. Murthy, Alessandro Hammond, Thoriso Diale, Fu Siong Ng, Martin Cowie

    Objective. It remains unclear which architecture best sorts 12-lead electrocardiograms into diagnostic superclasses, and whether added model complexity pays off. Methods. Using 21,375 PTB-XL records under one patient-level split, we compared a Mamba-style state space model, a residual convolutional network, a bidirectional long short-term memory network, a convolutional-recurrent network with attention, soft-voting ensembles of these networks, and MiniRocket features with LightGBM. Each record took the superclass of its highest-likelihood diagnostic code, and we scored saved predictions with paired patient-level bootstrap intervals. Results. No model clearly outperformed MiniRocket with LightGBM, which needs no graphics processor. The ensemble of the three deep models with the highest validation macro F1 score reached 0.656, against 0.645 for MiniRocket with LightGBM (difference +0.011, 95% confidence interval -0.007 to +0.031), and an ensemble of all four deep models reached 0.657. An exploratory ensemble, whose members we chose after seeing test results, reached 0.665 and was the only ensemble whose interval excluded zero (+0.021, 0.002 to 0.040); we regard that margin as optimistic. Hypertrophy was the hardest class (F1 0.33 to 0.41), and differences in its recall mostly reflected threshold placement. Conclusions. Under one shared split, deep ensembles added little over a classical pipeline. Significance. These results give biomedical informatics researchers a statistically grounded reference for judging whether complex models justify their cost on this benchmark. With one dataset, one split, one training seed per model, and no external validation, they do not show readiness for clinical use.

  • Open Access

    Does Replacing SOFA-1 with SOFA-2 Change Mortality Discrimination and Calibration Across Patient Subgroups? A Paired Analysis in MIMIC-IV

    by Keshav Balakrishna, Vivaan Bhatt, Alessandro Hammond, Romain Pirracchio, Adrian H. Zai

    Background: The Sequential Organ Failure Assessment (SOFA) score describes organ dysfunction in intensive care. SOFA-2, published in 2025, updates the 1996 score (SOFA-1). It is unknown whether the update changes mortality discrimination and calibration within patient subgroups. Methods: We analyzed 85,228 first ICU stays per hospitalization (65,354 adults) in MIMIC-IV v3.1. We scored SOFA-1 (two prespecified conventions for intubated patients) and SOFA-2 from the same data over the same first 24 hours. The primary outcome was in-hospital mortality; ICU mortality was secondary. Using a paired patient-level bootstrap (5,000 replicates), we estimated AUROC overall and by sex, race and insurance; the paired change between scores; subgroup gaps in AUROC and the change in those gaps; and descriptive calibration. The protocol was committed before any analysis relating scores to mortality. Results: In-hospital death occurred in 9,468 stays (11.1%). AUROC was 0.762 for SOFA-2, 0.743 for SOFA-1 as charted and 0.735 for SOFA-1 under the community convention; SOFA-2 minus SOFA-1 was +0.019 (+0.016 to +0.023) and +0.027 (+0.023 to +0.031). Swapping single domains showed that the respiratory domain accounted for the whole gain, about 74% of it through the SpO2/FiO2 fallback. Subgroup gaps changed against SOFA-1 as charted (male–female +0.021; White–Black +0.025), driven by the brain-domain rule, but not against the community convention. The White–Black change was not seen in patients under 65, and neither change was consistent across ICU types. Calibration differences between groups were large but changed little between scores (|Δ log O/E| ≤ 0.045). Insurance-group differences largely disappeared in patients under 65, whereas race-group differences did not. Conclusions: SOFA-2 modestly improved overall discrimination for in-hospital mortality, mainly through its respiratory domain. Changes in subgroup performance gaps were small. They depended on how SOFA-1 handles intubated patients, partly reflected age, and were not consistent across ICU types. These are descriptive associations in a single database; we draw no causal or fairness conclusions.

  • Open Access

    Reporting of Pericardial Adverse Events with Immune Checkpoint Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System

    by Keshav Balakrishna, Vivaan Bhatt, Alessandro Hammond, Melat Mezgebu Bawoke, Michael G. Fradley, Daniel A. Zlotoff, Tomas G. Neilan

    Background. Immune checkpoint inhibitors (ICIs) can cause immune-related adverse events in almost any organ. While myocarditis has received the most attention, data on pericardial disease with ICI use are limited. We examined pericardial adverse event reporting with nine ICIs using the FDA Adverse Event Reporting System (FAERS). Methods. We combined legacy AERS and current FAERS quarterly files from January 2011 to June 2026 into 18,629,240 unique cases, deduplicated by case number, and removed cases the FDA had listed as deleted. ICI exposure was identified from generic names, brand names, development code names and the active-ingredient field. Pericardial events were defined by seven MedDRA preferred terms. We estimated reporting odds ratios (ROR), proportional reporting ratios (PRR), Bayesian information components (IC) and empirical Bayes geometric means (EBGM). We also examined myocarditis co-reporting, time trends, a comparison with other antineoplastic agents, a MedDRA query-based outcome, and 14 alternative definitions. Results. The analysis included 18,514,045 cases: 277,434 involved an ICI, 34,792 carried a pericardial term, and 1,680 had both. Pericardial events were reported disproportionately with ICIs (ROR 3.35 (95% CI 3.19 to 3.52); PRR 3.34; IC025 1.62). Eight of nine agents had a ROR above 1 (3.32 to 5.63). Among the most frequently reported terms, estimates were highest for cardiac tamponade (5.59 (95% CI 4.98 to 6.28)), followed by pericardial effusion (3.83 (95% CI 3.60 to 4.07)) and pericarditis (2.09 (95% CI 1.89 to 2.31)). After removing cases that also reported myocarditis, the ROR was 3.13 (95% CI 2.98 to 3.30). Most sensitivity analyses gave similar estimates (ROR 3.13 to 3.47); defining exposure by generic drug names alone, which identified only 44% of exposed cases, gave 3.99. Compared with cases naming other L01 antineoplastic agents, the ROR was 1.13 (95% CI 1.08 to 1.19): 1.28 (95% CI 1.20 to 1.36) for ICI-only cases and 0.96 (95% CI 0.89 to 1.04) when another antineoplastic was also named. The ICI-specific reporting odds ratio fell each quarter (odds ratio 0.977 per quarter, 95% CI 0.973 to 0.980). Conclusions. In FAERS, pericardial events were reported more often with ICIs than with other drugs across most agents and terms; however, incidence and causation cannot be determined. The excess over other antineoplastic agents was small, and reporting disproportionality declined over time. These findings support clinical awareness of pericardial disease in patients receiving ICIs and warrant study in data that can measure incidence.